Skip to main content
. 2006 Aug;118(4):527–538. doi: 10.1111/j.1365-2567.2006.02395.x

Figure 1.

Figure 1

Disease course and interferon-gamma (IFN-γ) expression in wild-type (WT) and tumour necrosis factor receptor (TNFR1)–/– mice. (a) WT (black circles, n = 7) and TNFR1–/– (white circles, n = 4) mice were immunized with myelin olidodendrocyte glycoprotein peptide 35–55 (MOGp35–55)/complete Freund's adjuvant (CFA) on day 0 and day 7, and pertussis toxin was administered intraperitoneally (i.p.) on day 0 and day 2. Mice were scored daily as described in Methods. Results are shown as mean ± SEM. Representative of four replicate experiments (n = 4–8 WT or TNFR1–/– mice per group in each experiment). (b) IFN-γ mRNA expression was assessed by real-time polymerase chain reaction (PCR) in spinal cords of wild-type (black bars) and TNFR1–/– (grey bars) unmanipulated mice (naive) or mice with grade 2 or grade 4 disease. Values are expressed as arbitrary units normalized to 18S expression, mean ± SEM, n = 4 mice. *P < 0·05. ND, not detectable; NT, not tested, as TNFR1–/– mice did not develop disease more severe than grade 2.